August 2017

New Product - Alecensa

Alecensa (alectinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and rearranged during transfection (RET) tyrosine kinase. Alecensa is indicated for the treatment of ALK positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on or are intolerant to crizotinib. Alecensa 150 mg capsules are available in a multipack of 224 (4 packs of 56).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au